1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 20,400 | 20,800 | 13:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | DUALITYBIO-B (09606): ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE RMB SHARE ISSUE | - | HKEx | ||
| Mi | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| Mi | DUALITYBIO-B Plans A Share Listing on STAR Market, Passes Shanghai Regulatory Bureau Tutoring Acceptance | 1 | AASTOCKS | ||
| Mi | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE ON COUNSELLING FROM SHANGHAI SECURITIES REGULATORY BUREAU REGARDING PROPOSED LISTING OF RMB ... | 1 | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.06. | DUALITYBIO-B (09606): (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING ... | - | HKEx | ||
| 03.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 26.05. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 19.05. | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PLAN UNDER THE REPURCHASE MANDATE AND PROPOSED INCREASE IN SHAREHOLDING BY CHAIRMAN OF ... | 3 | HKEx | ||
| 13.05. | DUALITYBIO-B (09606): INSIDE INFORMATION NOTICE OF EXERCISE OF THE DB-1311/BNT324 COST & PROFIT/LOSS SHARING OPTION | 2 | HKEx | ||
| 29.04. | DUALITYBIO-B (09606): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON APRIL 29, 2026 | 2 | HKEx | ||
| 14.04. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON APRIL 29, 2026 | 3 | HKEx | ||
| 14.04. | DUALITYBIO-B (09606): NOTICE OF THE EXTRAORDINARY GENERAL MEETING | 3 | HKEx | ||
| 14.04. | DUALITYBIO-B (09606): (1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTION; (2) PROPOSED ... | 1 | HKEx | ||
| 13.04. | DUALITYBIO-B (09606): (1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES ... | 5 | HKEx | ||
| 11.04. | BioNTech SE: BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer | 1.316 | GlobeNewswire (Europe) | Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent... ► Artikel lesen | |
| 11.04. | BioNTech SE: BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs | 2.209 | GlobeNewswire (Deutschland) | Trastuzumab Pamirtecan, ein innovativer gegen HER2 gerichteter Antikörper-Wirkstoff-Konjugat-Kandidat, erreichte den primären Wirksamkeitsendpunkt in einer Phase-2-Kohorte bei stark vorbehandelten Patientinnen... ► Artikel lesen | |
| 09.04. | DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer | 512 | PR Newswire | SHANGHAI, April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the "Company", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational... ► Artikel lesen | |
| 09.04. | DUALITYBIO-B (09606): INSIDE INFORMATION BIOLOGICS LICENSE APPLICATION FOR DB-1303/BNT323 FOR UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER IN ... | 1 | HKEx |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,95 | +1,43 % | Zelltherapien rücken in den Mittelpunkt: Warum Mesoblast von einem grundlegenden Wandel in der Biotechnologie profitieren könnte | ||
| MODERNA | 43,100 | -0,10 % | Fendi inszeniert Couture in der Galleria Nazionale d'Arte Moderna e Contemporanea | ||
| PALATIN TECHNOLOGIES | 13,920 | +2,28 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,325 | +3,83 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors | Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 88,33 | 0,00 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 46,130 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| QIAGEN | 31,980 | -0,28 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,000 | -0,07 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| IMMUNOME | 18,380 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 30,960 | +0,06 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| MBX BIOSCIENCES | 35,510 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism | Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial Results consistent with restoration of systemic PTH activity through serum calcium... ► Artikel lesen | |
| IMMUNOVANT | 33,620 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 267,07 | +0,18 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 8,210 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 34,830 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen |
DUALITY BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +5,15 % bei einem Aktienkurs von 20,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DUALITY BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.